Sinsin Pharmaceutical Co. Ltd (002800) - Total Assets
Based on the latest financial reports, Sinsin Pharmaceutical Co. Ltd (002800) holds total assets worth ₩136.11 Billion KRW (≈ $92.24 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sinsin Pharmaceutical Co. Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Sinsin Pharmaceutical Co. Ltd's total assets have evolved over time, based on quarterly financial data. Also see market cap of Sinsin Pharmaceutical Co. Ltd for the company's overall valuation and market capitalisation.
Sinsin Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Sinsin Pharmaceutical Co. Ltd's total assets of ₩136.11 Billion consist of 39.8% current assets and 60.2% non-current assets. Review total liabilities of Sinsin Pharmaceutical Co. Ltd to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩539.85 Million | 0.4% |
| Accounts Receivable | ₩30.61 Billion | 23.6% |
| Inventory | ₩16.64 Billion | 12.9% |
| Property, Plant & Equipment | ₩65.72 Billion | 50.8% |
| Intangible Assets | ₩580.53 Million | 0.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Sinsin Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 002800 stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinsin Pharmaceutical Co. Ltd's current assets represent 39.8% of total assets in 2024, a decrease from 50.2% in 2016.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2024, down from 0.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 50.8% of total assets.
Sinsin Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Sinsin Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Sinsin Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.95 | 0.94 | 1.15 |
| Quick Ratio | 0.64 | 0.67 | 0.79 |
| Cash Ratio | 0.00 | 0.05 | 0.00 |
| Working Capital | ₩-3.28 Billion | ₩-3.75 Billion | ₩5.30 Billion |
Sinsin Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Sinsin Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.26 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.1% |
| Total Assets | ₩129.48 Billion |
| Market Capitalization | $45.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sinsin Pharmaceutical Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sinsin Pharmaceutical Co. Ltd's assets grew by 4.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sinsin Pharmaceutical Co. Ltd (2016–2024)
The table below shows the annual total assets of Sinsin Pharmaceutical Co. Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩129.48 Billion ≈ $87.75 Million |
+4.08% |
| 2023-12-31 | ₩124.41 Billion ≈ $84.31 Million |
+2.64% |
| 2022-12-31 | ₩121.21 Billion ≈ $82.14 Million |
+6.04% |
| 2021-12-31 | ₩114.31 Billion ≈ $77.46 Million |
-3.24% |
| 2020-12-31 | ₩118.13 Billion ≈ $80.06 Million |
-8.59% |
| 2019-12-31 | ₩129.24 Billion ≈ $87.58 Million |
+19.75% |
| 2018-12-31 | ₩107.92 Billion ≈ $73.14 Million |
+36.86% |
| 2017-12-31 | ₩78.85 Billion ≈ $53.44 Million |
+14.60% |
| 2016-12-31 | ₩68.81 Billion ≈ $46.63 Million |
-- |
About Sinsin Pharmaceutical Co. Ltd
Sinsin Pharmaceutical Co., Ltd manufactures and sells pharmaceutical products in South Korea. It offers various medicinal products, such as plaster, aerosol, topical liquid, emollient, hygiene, and ointment products, as well as adhesive bandages, mosquito repellents, anti-perspirants, cooling sheets, bruise treatment creams, and other products. The company also develops transdermal drug delivery … Read more